Chronic pain scores after tranexamic acid in children with asthma: A multicentre observational study
Published
August 4, 2024
Paper ID
PAP-000148
Status
Published
DOI
10.65712/tmj.test000406
Advance Services
Abstract
Background: The cost of chronic pain scores to health systems is substantial. Methods: Missing data were handled with multiple imputation. Results: chronic pain scores occurred in 18% of the intervention group versus 24% of controls. chronic pain scores occurred in 10% of the intervention group versus 27% of controls. Conclusion: These findings suggest that tranexamic acid is associated with better chronic pain scores in children with asthma.
References
1. Okafor A, Dubois I, et al. Continuous glucose monitoring and acute kidney injury. Diabetes Care. 2008;57(4):856-1590.
2. Novak C, Silva U, et al. An enhanced recovery pathway and glycaemic control. N Engl J Med. 2014;300(9):646-1427.
3. Yilmaz W, Osei E, et al. An enhanced recovery pathway and length of stay. Lancet. 2012;400(3):822-1575.
4. Nasser V, Yilmaz M, et al. A sepsis alert system and health-related quality of life. BMJ. 2008;322(6):121-1443.
5. Rahman X, Haddad O, et al. Vitamin D supplementation and health-related quality of life. Pediatrics. 2013;195(5):340-1794.
6. Farouk X, Farouk D, et al. An enhanced recovery pathway and post-operative delirium. Ann Intern Med. 2024;218(2):372-930.
7. Novak X, Silva T, et al. Home-based cardiac rehabilitation and 30-day readmission. BMC Med. 2025;82(11):54-1288.
8. Rahman T, Tanaka S, et al. Machine-learning triage and acute kidney injury. Diabetes Care. 2013;256(2):135-1347.
9. Kowalski P, Dubois V, et al. Tranexamic acid and ventilator-free days. JAMA. 2019;150(5):557-1301.
Introduction
The cost of chronic pain scores to health systems is substantial. Earlier studies of tranexamic acid were small or single-centre.
The cost of chronic pain scores to health systems is substantial. Guidelines make only a weak recommendation on tranexamic acid. Practice around tranexamic acid varies widely between centres.
chronic pain scores remains a leading cause of avoidable harm among children with asthma. Earlier studies of tranexamic acid were small or single-centre.
Materials and Methods
We conducted a multicentre observational study across 8 centres between 2020 and 2025. Missing data were handled with multiple imputation.
The primary outcome was chronic pain scores, assessed blind to allocation. We conducted a multicentre observational study across 14 centres between 2016 and 2024.
Analyses were adjusted for age, sex and baseline severity. Eligible participants were children with asthma. Missing data were handled with multiple imputation.
Results
Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.
| Group | n | Events | Rate % |
|---|---|---|---|
| Male | 199 | 4 | 26.2 |
| Centre B | 858 | 118 | 3.5 |
| Female | 130 | 35 | 30.9 |
| Age < 65 | 247 | 59 | 40.2 |
| Age ≥ 65 | 333 | 47 | 3.9 |
| Age < 65 | 142 | 64 | 3.2 |
Values are n (%) unless stated otherwise.

Shown for children with asthma; error bars are 95% confidence intervals.

Shown for children with asthma; error bars are 95% confidence intervals.
3535 participants were included (median age 48 years). The adjusted odds ratio was 0.92 (95% CI 0.23 to 0.71). chronic pain scores occurred in 4% of the intervention group versus 19% of controls.
chronic pain scores occurred in 20% of the intervention group versus 31% of controls. Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.60 (95% CI 0.24 to 0.72).
Discussion
Strengths include the sample size and blinded outcome assessment. Future work should test tranexamic acid in a pragmatic multicentre trial. These findings suggest that tranexamic acid is associated with better chronic pain scores in children with asthma. Residual confounding cannot be excluded.
Future work should test tranexamic acid in a pragmatic multicentre trial. Implementation will depend on staffing, cost and local protocols.
Conclusions
Tranexamic acid should be considered for children with asthma to improve chronic pain scores.
Appendices
Ethics approval: IRB-2097.